Wang Aimin, Xiao Zhiming, Zhou Liping, Zhang Juan, Li Xiangmin, He Qingchun
a Department of Emergency , Xiangya Hospital, Central South University , Changsha , Hunan , China and.
b Department of Gastroenterology , The Third Hospital of Xiangya, Central South University , Changsha , Hunan , China.
Pharm Biol. 2016;54(1):146-50. doi: 10.3109/13880209.2015.1024330. Epub 2015 Apr 8.
Atractylenolide I (AT-I), an active compound isolated from Atractylodes macrocephala Koidz (Compositae), shows several pharmacological activities.
Our present study is designed to investigate the protective effect of AT-I on systemic inflammation in the mouse model of sepsis created by cecal ligation and puncture (CLP), and explore the possible mechanism.
Sepsis mouse model was established by CLP, and the tested dosages of AT-I were 10, 20, and 40 mg/kg (ip). Pro-inflammatory cytokines in serum (TNF-α, IL-1β and IL-6) were determined by the ELISA method; serum lipopolysaccharide (LPS) level was measured by the Limulus Amebocyte Lysate (LAL) test; white blood cells (WBC) were counted by Blood cell analyzer; contents of alanine transaminase (ALT), aspartate transarninase (AST), creatinine (Cre), and blood urea nitrogen (BUN) in serum were determined by automatic biochemistry analyzer. For survival rate tests, CLP mice were observed within 7 days, and body temperature was measured at 0, 4, 8, 12, 24, 48 and 72 h after surgery.
Our results indicated that AT-I significantly increased the survival rate of mice with sepsis (p < 0.05), whereas the WBCs and levels of LPS, pro-inflammatory cytokines (TNF-α, IL-1β and IL-6), ALT, AST, Cre, and BUN decreased significantly after treatment with AT-I (p < 0.05).
In conclusion, the AT-I ameliorates sepsis syndrome by reduction of pro-inflammatory cytokines and LPS, and provides an improvement in liver and kidney functions.
白术内酯 I（AT-I）是从白术（菊科）中分离出的一种活性化合物，具有多种药理活性。
本研究旨在探讨 AT-I 对盲肠结扎穿刺（CLP）所致脓毒症小鼠模型全身炎症的保护作用，并探讨其可能的机制。
通过 CLP 建立脓毒症小鼠模型，AT-I 的受试剂量为 10、20 和 40 mg/kg（腹腔注射）。采用酶联免疫吸附测定法（ELISA）检测血清中促炎细胞因子（TNF-α、IL-1β 和 IL-6）；采用鲎试剂法检测血清脂多糖（LPS）水平；采用血细胞分析仪计数白细胞（WBC）；采用自动生化分析仪检测血清中丙氨酸转氨酶（ALT）、天冬氨酸转氨酶（AST）、肌酐（Cre）和血尿素氮（BUN）的含量。进行生存率测试时，观察 CLP 小鼠 7 天，并在术后 0、4、8、12、24、48 和 72 小时测量体温。
我们的结果表明，AT-I 显著提高了脓毒症小鼠的生存率（p < 0.05），而用 AT-I 治疗后，白细胞、LPS、促炎细胞因子（TNF-α、IL-1β 和 IL-6）、ALT、AST、Cre 和 BUN 的水平显著降低（p < 0.05）。
总之，AT-I 通过降低促炎细胞因子和 LPS 改善脓毒症综合征，并改善肝肾功能。
